New collaborations that have expanded our research portfolio are with the Marc and Jennifer Lipschultz Precision Immunology Institute and the Icahn Institute for Genomics and Multiscale Biology, with a special focus on discovery of new arthritis, autoimmune and inflammation regulatory genes.
Active research activities also include ongoing state-of-the-art science in rheumatoid arthritis. We are actively participating in a phase 1 clinical trial of CD19-targeted chimeric antigen receptor (CAR) T cells for the treatment of severe, refractory systemic lupus erythematosus with plans to extend to other autoimmune diseases. The Division of Rheumatology is also leading new programs and initiatives in fibromyalgia, and immunophenotyping in autoimmunity and other chronic clinical immunological disorders. Our team is currently furthering the development of a lupus cohort and registry, the latter supported in part by the Rheumatology Research Foundation.